# SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

> **NCT05629962** · PHASE3 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 2285 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
- COVID-19

## Interventions

- **DRUG:** Bemnifosbuvir (BEM)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05629962
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-25
- **Primary completion:** 2024-04-25
- **Final completion:** 2024-05-30
- **Target enrollment:** 2285 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629962, "SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05629962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*